Clinical Significance of a Highly Sensitive Analysis for Gene Dosage and the Expression Level of MYCN in Neuroblastoma

Journal of Pediatric Surgery

Volumn 39, Issue 1, 2004, Pages 63-68

  Tanaka, Shinji ^a,b   Tajiri, Tatsuro ^a,b   Noguchi, Shin Ichi ^a,b   Shono, Kumiko ^a,b   Ihara, Kenji ^a,b   Hara, Toshiro ^a,b   Suita, Sachiyo ^a,b  

^a Kyushu University ^*

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

FISH; MYCN; Neuroblastoma; Quantitative polymerase chain reaction

Indexed keywords

ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYCN GENE; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0345770652     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2003.09.015     Document Type: Article

References (25)

1. Fong CT, Drecopoli NC, White PS, et al: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A 86:3753-3757, 1989
2. Bown N, Cotterill SJ, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in neuroblastoma. N Engl J Med 340:1954-1961, 1999
3. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science 224:1121-1124, 1984
4. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
5. Lutz W, Stohr M, Schurmann J, et al: Coditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13:803-812, 1996
6. Raschella G, Romeo A, Pucci S. et al: Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: Implication for N-myc-MAX complex formation. Cancer Res 54:2251-2255, 1994
7. Bordow SB, Norris MD, Haber PS, et al: Prognostic Significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 16:3286-3294, 1998
8. Seeger RC, Wada R, Brodeur GM, et al: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49, 1988
9. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastoma. J Natl Cancer Inst 85:337-384, 1993
10. Slave I, Ellenbogen R, Jung WH, et al: myc gene amplification and expression in primary human neuroblastoma. Cancer Res 50:1459-1463, 1990
11. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al: Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993
12. Tajiri T, Shono K, Fujii Y, et al: Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence In Situ Hybridization. J Pediatr Surg 34:1615-1619, 1999
13. Tajiri T, Tanaka S, Shono K, et al: Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett 166:89-94, 2001
14. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
15. Tsuda T, Obara M, Hirano H, et al: Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer 60:820-826, 1987
16. Taylor SR, Blatt J, Costantino JP, et al: Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer 62:749-754, 1988
17. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
18. Kusafuka T, Fukuzawa M, Oue T, et al: Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 32:1175-1180, 1997
19. Kaneko M, Nishihira H, Mugishima H, et al: Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Med Pediatr Oncol 31:1-7, 1998
20. Raggi CC, Bagnoni ML, Tonini GP, et al: Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system. Clin Chem 45:1918-1924, 1999
21. Yan W. Linderborg J, Suminen J, et al: Stage-specific regulation of stem cell factor gene expression in the rat seminiferous epithelium. Endocrinology 140:1499-1504, 1999
22. Chan HSL, Gallie BL, DeBoer G, et al: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3:1699-1706, 1997
23. Matsunaga T, Shirasawa H, Hishiki T, et al: Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening. Clin Cancer Res 6:3199-3204, 2000
24. Evan GI, Wyllie AH, Gilbert CS, et al: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128, 1992
25. Lutz W, Fulda S, Jeremias I, et al: MYCN, and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene 17:339-346, 1998